https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ADiscovery_and_development_of_gliflozins%2F18%2FenTranslations:Discovery and development of gliflozins/18/en - Revision history2026-10-12T03:37:33ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:Discovery_and_development_of_gliflozins/18/en&diff=114404&oldid=prevFuzzyBot: Importing a new version from external source2024-02-14T00:56:20Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>=== T-1095 ===<br />
[[File:T-1095.svg|thumb|The structure of T-1095]]<br />
Because Phlorizin is a nonselective inhibitor with poor oral bioavailability, a phlorizin derivative was synthesised and called T-1095. T-1095 is a [[methyl carbonate]] prodrug that is absorbed into the circulation when given orally, and is rapidly converted in the liver to the active metabolite T-1095A. By inhibiting [[SGLT-1]] and [[SGLT-2]], urinary glucose excretion increased in diabetic animals. T-1095 did not proceed in clinical development, probably because of the inhibition of SGLT-1 but non-selective SGLT inhibitors may also block [[Glucose transporter|glucose transporter 1]] (GLUT-1). Because 90% of filtered glucose is reabsorbed through SGLT-2, research has focused specifically on SGLT-2. Inhibition of SGLT-1 may also lead to the genetic disease [[glucose-galactose malabsorption]], which is characterized by severe diarrhea.</div>FuzzyBot